newsfilter
← Latest News
GlobeNewswire·

Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights

AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, reaffirm alignment on